Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS3797 Dose Escalation in Healthy Adults
NCT05701826Phase 1Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HRS-3797 (6 arms), sponsored by Fujian Shengdi Pharmaceuticals. Primary endpoints: Maximum T1 Suppression, Time to Maximum T1 Suppression and 12 more. Started Feb 2023; status: completed.
02
Drugs
HRS-3797
Beyond the preview
Go deeper on NCT05701826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701826.